Business Wire

Mercans Adds Industry Veteran Steve Goldberg to its Board

4.10.2022 17:07:00 EEST | Business Wire | Press release

Share

Mercans, the global payroll technology leader, has announced that Steve Goldberg has joined its board as a non-executive director. The addition of an industry veteran to Mercans’ board follows several recently announced corporate governance changes to strengthen the board and executive management team of the global payroll and EOR service provider.

When announcing Steve Goldberg’s appointment, Mercans’ board said, “We welcome Steve as a non-executive director to the board and believe that his long-term industry experience and insights will bring unique perspectives to Mercans. Steve’s strategic vision for the global payroll and HCM industry aligns well with Mercans’ strategy. We are confident that his leadership will further accelerate Mercans’ growth and strengthen its ability to deliver award-winning global payroll technology.”

Steve Goldberg's 30+ year career on all sides of HR and Payroll technology includes HR executive roles across 3 continents, serving as HCM product strategy leader and spokesperson at PeopleSoft, and co-founding boutique recruiting tech and change management firms. Steve’s uniquely diverse perspectives have been leveraged by both solution vendors and corporate HR teams, and in practice leader roles at Bersin and Ventana Research. He holds an MBA in HR, is widely published and is a featured speaker around the globe. He has been recognized as a Top 100 HRTech Influencer.

“We are delighted by the appointment of Steve Goldberg to the Board. Steve brings not only years of industry experience but also adds an independent and fresh perspective to Mercans’ strategy and governance structure,” said Tatjana Domovits, Mercans’ Group CEO.

Mercans’ global payroll technology has disrupted the global payroll industry by allowing customers, HCM, and payroll services providers to move away from managing various in-country services providers and outdated software solutions. Mercans’ proprietary global payroll platform HR Blizz delivers payroll processing capabilities and integrations with local tax authorities across 160 countries and allows customers to fully consolidate and digitalize their international payroll function.

About Mercans

Mercans is a global leader in payroll technology. Mercans’ revolutionary HR Blizz global payroll platform enables SMBs & Enterprise businesses to manage payrolls across 160 countries. With 20 years of global payroll expertise, Mercans delivers the full spectrum of HR services through a single, secure global platform.

Visit www.mercans.com

LinkedIn

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mohsin Khan
hello@mercans.com
Berkeley Square House, 2nd Floor, Berkeley Square,
London, UK

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 13:17:00 EEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release

Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye